Pharmanutra Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Pharmanutra wird ein jährliches Gewinn- und Umsatzwachstum von 25.8% bzw. 9.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 25.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 28.3% betragen.

Wichtige Informationen

25.8%

Wachstumsrate der Gewinne

25.9%

EPS-Wachstumsrate

Personal Products Gewinnwachstum	7.8%
Wachstumsrate der Einnahmen	9.1%
Zukünftige Eigenkapitalrendite	28.3%
Analystenabdeckung	Low
Zuletzt aktualisiert	14 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 23

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Mar 10

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Feb 17

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Feb 01

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Jan 18

Is Pharmanutra (BIT:PHN) A Risky Investment?

Jan 04

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

Dec 22

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Dec 08

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 23

Gewinn- und Umsatzwachstumsprognosen

BIT:PHN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	147	25	23	27	2
12/31/2025	129	21	19	22	2
12/31/2024	113	17	15	18	2
3/31/2024	101	11	2	12	N/A
12/31/2023	101	13	-1	12	N/A
9/30/2023	95	11	-5	12	N/A
6/30/2023	93	13	-18	12	N/A
3/31/2023	88	16	-15	14	N/A
12/31/2022	83	15	-9	17	N/A
9/30/2022	79	16	-5	19	N/A
6/30/2022	76	15	10	19	N/A
3/31/2022	73	15	14	20	N/A
12/31/2021	68	14	15	20	N/A
9/30/2021	65	14	13	16	N/A
6/30/2021	60	11	12	15	N/A
3/31/2021	57	14	13	15	N/A
12/31/2020	57	14	10	12	N/A
9/30/2020	58	14	11	11	N/A
6/30/2020	58	14	7	11	N/A
3/31/2020	55	9	4	9	N/A
12/31/2019	54	8	7	12	N/A
9/30/2019	49	8	3	8	N/A
6/30/2019	50	9	7	9	N/A
3/31/2019	48	9	6	8	N/A
12/31/2018	47	9	6	6	N/A
9/30/2018	44	8	5	6	N/A
6/30/2018	41	7	5	6	N/A
3/31/2018	40	6	5	6	N/A
12/31/2017	38	6	N/A	6	N/A
9/30/2017	37	5	N/A	N/A	N/A
6/30/2017	35	5	N/A	N/A	N/A
3/31/2017	34	4	N/A	N/A	N/A
12/31/2016	33	4	N/A	6	N/A
12/31/2015	26	3	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PHNDas prognostizierte Gewinnwachstum (25.8% pro Jahr) liegt über der Sparquote (2.3%).

Ertrag vs. Markt: PHNDie Erträge des Unternehmens (25.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Italian (5.8% pro Jahr).

Hohe Wachstumserträge: PHNEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: PHNDie Einnahmen des Unternehmens (9.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Italian (4% pro Jahr).

Hohe Wachstumseinnahmen: PHNDie Einnahmen des Unternehmens (9.1% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PHNDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (28.3%)

Pharmanutra Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased to €59.33

Price target increased to €50.67

Price target increased to €45.00

Recent updates

First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)

Upcoming dividend of €0.85 per share

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020)

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

Investor sentiment improved over the past week

Price target increased to €59.33

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

Price target increased to €50.67

Investor sentiment improved over the past week

Price target increased to €45.00

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Upcoming dividend of €0.67 per share

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Is Pharmanutra (BIT:PHN) A Risky Investment?

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

New 90-day high: €33.70

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Market bids up stock over the past week

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: €28.80

Third quarter 2020 earnings released: EPS €0.18

New 90-day high: €27.20

First half earnings released

First half earnings released

New 90-day low - €22.40

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken